Bone-density drugs like Fosamax show promise in reducing triple negative breast cancer tumors, according to two studies presented at the San Antonio Breast Cancer Symposium. The findings come from data from the Women’s Health Initiative and an Israeli study of postmenopausal women.
Dr. Gabriel N. Hortobagyi, who directs the breast cancer research program at the University of Texas M.D. Anderson Cancer Center, told The New York Times:
“With tamoxifen and raloxifene, we have drugs that reduce estrogen receptor-positive tumors, but we’ve never had anything worth anything that prevented estrogen receptor-negative tumors.”
The next step is a randamized clinical trial to see if the findings hold up in a controlled setting. Hortobagyi told The Times:
“These are provocative data, but certainly not compelling, and not definitive.”